Summary
2.8200 0.0100(0.3559%)07/03/2024
Myomo Inc (MYO)
Myomo Inc (MYO)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -6.0000 | -6.0000 | -17.6642 | -5.0505 | -30.7125 | 355.9418 | -86.7606 | -98.7297 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 2.8200 | |
| Open | 2.8500 | |
| High | 2.8988 | |
| Low | 2.7700 | |
| Volume | 163,462 | |
| Change | -0.1800 | |
| Change % | -6.0000 | |
| Avg Volume (20 Days) | 136,109 | |
| Volume/Avg Volume (20 Days) Ratio | 1.20 | |
| 52 Week Range | 0.50 - 5.58 | |
| Price vs 52 Week High | -49.46% | |
| Price vs 52 Week Low | 467.86% | |
| Range | -1.0526 | |
| Gap Up/Down | -0.2300 | |
Fundamentals | ||
| Market Capitalization (Mln) | 80 | |
| EBIDTA | -10,746,738 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 21.5000 | |
| Book Value | 2.2500 | |
| Earnings Per Share | -1.7610 | |
| EPS Estimate Current Quarter | -0.4600 | |
| EPS Estimate Next Quarter | -0.3300 | |
| EPS Estimate Current Year | -1.8700 | |
| EPS Estimate Next Year | -1.2800 | |
| Diluted EPS (TTM) | -1.7610 | |
| Revenues | ||
| Profit Marging | -0.6858 | |
| Operating Marging (TTM) | -0.6793 | |
| Return on asset (TTM) | -0.3523 | |
| Return on equity (TTM) | -0.7147 | |
| Revenue TTM | 13,614,716 | |
| Revenue per share TTM | 2.5680 | |
| Quarterly Revenue Growth (YOY) | 1.2750 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 4,982,996 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 4.0384 | |
| Revenue Enterprise Value | 3.0309 | |
| EBITDA Enterprise Value | 0.1141 | |
| Shares | ||
| Shares Outstanding | 6,859,800 | |
| Shares Float | 5,566,571 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 3.58 | |
| Institutions (%) | 37.20 | |
06/05 17:58 EST - businesswire.com
Myomo to Present at the Sidoti Virtual Investor Conference on June 12-13, 2024
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul Gudonis, chairman and chief executive officer and David Henry, chief financial officer, will present and host one-on-one meetings with investors at the Sidoti Virtual Investor conference being held on June 12-13, 2024. Management's presentat.
Myomo to Present at the Sidoti Virtual Investor Conference on June 12-13, 2024
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul Gudonis, chairman and chief executive officer and David Henry, chief financial officer, will present and host one-on-one meetings with investors at the Sidoti Virtual Investor conference being held on June 12-13, 2024. Management's presentat.
05/08 22:03 EST - seekingalpha.com
Myomo, Inc. (MYO) Q1 2024 Earnings Call Transcript
Myomo, Inc. (NYSE:MYO ) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Kim Golodetz - LHA Investor Relations Paul Gudonis - Chief Executive Officer Dave Henry - Chief Financial Officer Conference Call Participants Scott Henry - AGP Anthony Vendetti - Maxim Group Sean Lee - H.C. Wainwright Ben Haynor - Lake Street Capital Markets Edward Woo - Ascendiant Capital Operator Good day, and welcome to the Myomo First Quarter 2024 Earnings Conference Call.
Myomo, Inc. (MYO) Q1 2024 Earnings Call Transcript
Myomo, Inc. (NYSE:MYO ) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Kim Golodetz - LHA Investor Relations Paul Gudonis - Chief Executive Officer Dave Henry - Chief Financial Officer Conference Call Participants Scott Henry - AGP Anthony Vendetti - Maxim Group Sean Lee - H.C. Wainwright Ben Haynor - Lake Street Capital Markets Edward Woo - Ascendiant Capital Operator Good day, and welcome to the Myomo First Quarter 2024 Earnings Conference Call.
05/06 08:30 EST - businesswire.com
Myomo Announces First Lump Sum Reimbursements for MyoPros Delivered to Medicare Part B Beneficiaries Under New CMS Fees
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that the Centers for Medicare & Medicaid Services (“CMS”), through their regional contractors known as the DME MACs, have remitted and paid lump sum reimbursements to the Company and are beginning to reimburse orthotics and prosthetics (“O&P”).
Myomo Announces First Lump Sum Reimbursements for MyoPros Delivered to Medicare Part B Beneficiaries Under New CMS Fees
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that the Centers for Medicare & Medicaid Services (“CMS”), through their regional contractors known as the DME MACs, have remitted and paid lump sum reimbursements to the Company and are beginning to reimburse orthotics and prosthetics (“O&P”).
05/01 17:21 EST - businesswire.com
Myomo to Report First Quarter Financial Results on May 8, 2024
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the first quarter ended March 31, 2024 on May 8, 2024. The Company will host a conference call the same day, Wednesday May 8, 2024 at 4:30 p.m. ET with prepared remarks by Paul R. Gudonis, chairman and chief e.
Myomo to Report First Quarter Financial Results on May 8, 2024
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the first quarter ended March 31, 2024 on May 8, 2024. The Company will host a conference call the same day, Wednesday May 8, 2024 at 4:30 p.m. ET with prepared remarks by Paul R. Gudonis, chairman and chief e.
03/28 16:05 EST - businesswire.com
Myomo Appoints Heather Getz to its Board of Directors
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Heather Getz as a Class II director and chair of its audit committee effective March 26, 2024, to serve until the 2025 annual meeting of stockholders. With this appointment, Myomo has seven directors. Ms. Getz brings more than 25 ye.
Myomo Appoints Heather Getz to its Board of Directors
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Heather Getz as a Class II director and chair of its audit committee effective March 26, 2024, to serve until the 2025 annual meeting of stockholders. With this appointment, Myomo has seven directors. Ms. Getz brings more than 25 ye.
03/13 06:55 EST - seekingalpha.com
Myomo's Revolutionary MyoPro Brace: A Buy In Neurological Mobility Aid
Myomo offers revolutionary MyoPro braces that enhance mobility for upper limb disabilities due to various neurological conditions. The company is experiencing a record number of orders, leading to sustainable revenue growth and expansion in the Chinese and German markets. Myomo's strategic focus includes scaling operations globally and investing in R&D to remain competitive and innovate in medical orthotics.
Myomo's Revolutionary MyoPro Brace: A Buy In Neurological Mobility Aid
Myomo offers revolutionary MyoPro braces that enhance mobility for upper limb disabilities due to various neurological conditions. The company is experiencing a record number of orders, leading to sustainable revenue growth and expansion in the Chinese and German markets. Myomo's strategic focus includes scaling operations globally and investing in R&D to remain competitive and innovate in medical orthotics.
03/10 03:00 EST - seekingalpha.com
Myomo, Inc.: In Motion To Accelerating Revenue Growth
Medicare decision created a multi-decade revenue growth opportunity. Soft Q1 guidance due to non-recurring timing issues. 2024 guidance gives only partial-year credit to reimbursement change.
Myomo, Inc.: In Motion To Accelerating Revenue Growth
Medicare decision created a multi-decade revenue growth opportunity. Soft Q1 guidance due to non-recurring timing issues. 2024 guidance gives only partial-year credit to reimbursement change.
03/07 20:10 EST - seekingalpha.com
Myomo, Inc. (MYO) Q4 2023 Earnings Call Transcript
Myomo, Inc. (NYSE:MYO) Q4 2023 Earnings Conference Call March 7, 2024 4:30 PM ET
Myomo, Inc. (MYO) Q4 2023 Earnings Call Transcript
Myomo, Inc. (NYSE:MYO) Q4 2023 Earnings Conference Call March 7, 2024 4:30 PM ET
03/07 19:01 EST - zacks.com
Myomo, Inc. (MYO) Reports Q4 Loss, Tops Revenue Estimates
Myomo, Inc. (MYO) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.29 per share a year ago.
Myomo, Inc. (MYO) Reports Q4 Loss, Tops Revenue Estimates
Myomo, Inc. (MYO) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.29 per share a year ago.
03/07 16:05 EST - businesswire.com
Myomo Reports Fourth Quarter and Full Year 2023 Financial Results
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three months and year ended December 31, 2023. Financial and operational highlights for the fourth quarter of 2023 include the following (all comparisons are with the fourth quarter of 2022): Total and product revenue was $4.
Myomo Reports Fourth Quarter and Full Year 2023 Financial Results
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three months and year ended December 31, 2023. Financial and operational highlights for the fourth quarter of 2023 include the following (all comparisons are with the fourth quarter of 2022): Total and product revenue was $4.
03/01 08:00 EST - businesswire.com
CMS Posts Final Medicare DMEPOS Fee Schedule Rate for the MyoPro®
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that on February 29, 2024, the Centers for Medicare & Medicaid Services (CMS) posted the final Medicare Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) fee schedule payment rates for the MyoPro®. The final average fee sche.
CMS Posts Final Medicare DMEPOS Fee Schedule Rate for the MyoPro®
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that on February 29, 2024, the Centers for Medicare & Medicaid Services (CMS) posted the final Medicare Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) fee schedule payment rates for the MyoPro®. The final average fee sche.
02/29 16:05 EST - businesswire.com
Myomo to Report Fourth Quarter Financial Results on March 7, 2024
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the fourth quarter and fiscal year ended December 31, 2023 on March 7, 2024. The Company will host a conference call the same day, Thursday March 7, 2024 at 4:30 p.m. ET with prepared remarks by Paul R. Gudoni.
Myomo to Report Fourth Quarter Financial Results on March 7, 2024
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the fourth quarter and fiscal year ended December 31, 2023 on March 7, 2024. The Company will host a conference call the same day, Thursday March 7, 2024 at 4:30 p.m. ET with prepared remarks by Paul R. Gudoni.
01/19 16:05 EST - businesswire.com
Myomo Announces Closing of $6 Million Registered Direct Offering of Common Stock Priced At-the-Market
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it has closed its previously announced registered direct offering of its common stock, priced at-the-market with certain new and existing institutional investors as well as certain insiders of the Company, for the purchase and sale of 1,578,948 s.
Myomo Announces Closing of $6 Million Registered Direct Offering of Common Stock Priced At-the-Market
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it has closed its previously announced registered direct offering of its common stock, priced at-the-market with certain new and existing institutional investors as well as certain insiders of the Company, for the purchase and sale of 1,578,948 s.
01/17 08:05 EST - businesswire.com
Myomo Announces $6 Million Registered Direct Offering of Common Stock Priced At-the-Market
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it has entered into securities purchase agreements with certain new and existing institutional investors as well as certain insiders of the Company for the purchase and sale of 1,578,948 shares of common stock (or common stock equivalents in lieu.
Myomo Announces $6 Million Registered Direct Offering of Common Stock Priced At-the-Market
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it has entered into securities purchase agreements with certain new and existing institutional investors as well as certain insiders of the Company for the purchase and sale of 1,578,948 shares of common stock (or common stock equivalents in lieu.
01/17 08:00 EST - businesswire.com
Myomo Reports Preliminary Fourth Quarter Revenue and Backlog
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced preliminary revenue and operating metrics for the fourth quarter of 2023. Revenue for the fourth quarter of 2023 is expected to be in the range of $4.6 million to $4.8 million, an increase of 14% to 19%, compared with the same period a year ago. The C.
Myomo Reports Preliminary Fourth Quarter Revenue and Backlog
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced preliminary revenue and operating metrics for the fourth quarter of 2023. Revenue for the fourth quarter of 2023 is expected to be in the range of $4.6 million to $4.8 million, an increase of 14% to 19%, compared with the same period a year ago. The C.
12/20 10:31 EST - zacks.com
What Makes Myomo, Inc. (MYO) a Good Fit for 'Trend Investing'
If you are looking for stocks that are well positioned to maintain their recent uptrend, Myomo, Inc. (MYO) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
What Makes Myomo, Inc. (MYO) a Good Fit for 'Trend Investing'
If you are looking for stocks that are well positioned to maintain their recent uptrend, Myomo, Inc. (MYO) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
12/12 07:00 EST - investorplace.com
7 Stock Winners That Are Up 1,000% or More in 2023
As you may already suspect, there are not a lot of stocks up 1000% year-to-date, but several stocks trading on major exchanges are up 1000% from their lows set earlier in the calendar year. There are also a few fairly-liquid over-the-counter listed stocks that qualify for this category, whether by gaining tenfold since January, or by surging tenfold from an earlier low.
7 Stock Winners That Are Up 1,000% or More in 2023
As you may already suspect, there are not a lot of stocks up 1000% year-to-date, but several stocks trading on major exchanges are up 1000% from their lows set earlier in the calendar year. There are also a few fairly-liquid over-the-counter listed stocks that qualify for this category, whether by gaining tenfold since January, or by surging tenfold from an earlier low.
12/01 13:32 EST - seekingalpha.com
Myomo: Market Severely Undervaluing Opportunity
Market undervalues MYO stock due to poor understanding of CMS process. MYO is able to generate revenues in excess of $100mm/yr. MYO valuation gap will close before February 2024, when the final CMS price is published.
Myomo: Market Severely Undervaluing Opportunity
Market undervalues MYO stock due to poor understanding of CMS process. MYO is able to generate revenues in excess of $100mm/yr. MYO valuation gap will close before February 2024, when the final CMS price is published.
11/20 16:16 EST - investorplace.com
3 Hot Penny Stocks to Buy in Q4 for Promising Potential
Penny stocks are typically companies that are trading below $5 per share. These companies are ones that can be risky to invest in.
3 Hot Penny Stocks to Buy in Q4 for Promising Potential
Penny stocks are typically companies that are trading below $5 per share. These companies are ones that can be risky to invest in.
11/07 18:28 EST - seekingalpha.com
Myomo, Inc. (MYO) Q3 2023 Earnings Call Transcript
Myomo, Inc. (MYO) Q3 2023 Earnings Call Transcript
Myomo, Inc. (MYO) Q3 2023 Earnings Call Transcript
Myomo, Inc. (MYO) Q3 2023 Earnings Call Transcript